TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06265727: A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Sponsor: Corbus Pharmaceuticals Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 348 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,023,790

Rescue Site Savings

+$2,002,770

Unlock Full NCT06265727 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06265727 Rescue Dossier →